$MNKD News

MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants

MannKind: New Approvals Majorly Increase MannKind's Prospects

MannKind Corporation 2026 Q2 - Results - Earnings Call Presentation

Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenue

MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload - Slideshow

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF - Slideshow

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14

MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary Fibrosis

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24

MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney Disease

MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients

Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval

MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis

MannKind At An Inflection Point: Pediatric Expansion Drives The Story